Status:
NOT_YET_RECRUITING
A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants
Lead Sponsor:
Zhejiang Wenda Pharma Technology LTD.
Conditions:
Healthy Participants
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participa...
Eligibility Criteria
Inclusion
- Aged 18 to 55 years (inclusive) at the time of informed consent.
- Body mass index (BMI) between 18 to 32 kg/m2 and male participant with body weight of ≥ 50.0 kg, female participant with body weight ≥ 45.0 kg
Exclusion
- Any major surgery within 12 weeks prior to Day 1, or any planned surgery during the study.
- Poor pill swallowing ability
Key Trial Info
Start Date :
June 30 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT06897813
Start Date
June 30 2025
End Date
December 31 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia, 3004